CARDIOTOXICITY
Clinical trials for CARDIOTOXICITY explained in plain language.
Never miss a new study
Get alerted when new CARDIOTOXICITY trials appear
Sign up with your email to follow new studies for CARDIOTOXICITY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Heart shield for chemo: carvedilol may guard against toxicity
Disease control CompletedThis early-phase study tested whether the heart medication carvedilol could safely prevent heart damage in breast cancer patients receiving chemotherapy with doxorubicin and/or trastuzumab. Researchers assigned 68 women to either usual care or carvedilol based on their risk of he…
Matched conditions: CARDIOTOXICITY
Phase: PHASE1 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated May 26, 2026 04:00 UTC
-
Exercise program aims to protect hearts of young cancer survivors
Disease control CompletedThis study looked at whether a special exercise program is practical and helpful for young cancer survivors (ages 18-45) who have mild heart problems from past treatment. 30 survivors joined the pilot study to test if they could stick with the program and if it improved their hea…
Matched conditions: CARDIOTOXICITY
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated May 26, 2026 03:54 UTC
-
Exercise may reverse Chemo-Related heart harm in young cancer survivors
Disease control CompletedThis study looked at whether aerobic exercise can help repair heart damage caused by a type of chemotherapy called anthracycline in childhood cancer survivors. About 47 long-term survivors over age 9 took part. The goal was to see if exercise could improve heart structure and fun…
Matched conditions: CARDIOTOXICITY
Sponsor: Connecticut Children's Medical Center • Aim: Disease control
Last updated May 26, 2026 03:53 UTC
-
Heart shield: common diabetes drug may protect cancer patients from Chemo-Induced heart damage
Disease control CompletedThis study tested whether dapagliflozin, a drug used for diabetes and heart failure, can prevent heart damage caused by anthracycline chemotherapy. 90 cancer patients took either dapagliflozin or a placebo daily for four months alongside their chemo. Researchers measured heart fu…
Matched conditions: CARDIOTOXICITY
Phase: PHASE2 • Sponsor: Hawler Medical University • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Heart scan predicts chemo and radiation damage in breast cancer patients
Knowledge-focused CompletedThis study looked at whether special heart scans (CMR) can spot early signs of heart damage in 150 breast cancer patients treated with chemotherapy and radiation. The goal was to predict cardiotoxicity, defined as a significant drop in heart function within a year after treatment…
Matched conditions: CARDIOTOXICITY
Sponsor: Oncology Institute of Southern Switzerland • Aim: Knowledge-focused
Last updated May 26, 2026 03:57 UTC
-
Which radiation is safer for the heart? new study investigates
Knowledge-focused CompletedThis study looked at 172 breast cancer patients to see how two types of radiation therapy—proton and photon—affect heart health. Researchers measured heart function and blood markers before, during, and up to one year after treatment. The goal was to understand which method might…
Matched conditions: CARDIOTOXICITY
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated May 26, 2026 03:53 UTC
-
CAR T-Cell therapy: hidden heart risks revealed in new study
Knowledge-focused CompletedThis study followed 44 adults with leukemia or lymphoma who received CAR T-cell therapy to see how their hearts were affected. Researchers used heart scans, blood tests, and quality-of-life surveys to track heart function over time. The goal was to find out how often heart proble…
Matched conditions: CARDIOTOXICITY
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated May 22, 2026 14:01 UTC
-
Lung cancer drug heart risks revealed in new study
Knowledge-focused CompletedThis study looked at how often heart problems happen in people with advanced lung cancer who take a type of targeted therapy called EGFR-TKIs. Researchers watched 100 patients to see if their heart's pumping strength dropped. The goal was to better understand and track these side…
Matched conditions: CARDIOTOXICITY
Sponsor: Taichung Veterans General Hospital • Aim: Knowledge-focused
Last updated May 22, 2026 13:55 UTC